Lymphoma & Plasma Cell Disorders
CHICAGO – Frontline use of chemoimmunotherapy is complicated.
Big survival gains were reported in patients with relapsed/refractory DLBCL treated with polatuzumab vedotin, bendamustine, and rituximab.
From the Journals
The good practice paper includes new information on pathology and use of PET/CT scanning in staging of disease.
The FDA granted accelerated approval based on results from the KEYNOTE-170 trial.
The drug is indicated for patients with CLL or SLL, with or without 17p deletion, who have had at least one prior therapy.
CHICAGO – The drug combination was evaluated in a phase 2 study of patients with previously untreated CLL.
CHICAGO – Could lenalidomide plus rituximab be a first-line option?
CHICAGO – Treatment with Hu5F9-G4 (5F9) produced “encouraging” antitumor activity in a phase 1b study of 22 patients.
CHICAGO – The study sheds light on the value of transplant after treatment with CAR T cells.
CHICAGO – ASH guideline coauthor explains the evidence behind the group’s recent guidelines on bone-modifying agents in multiple myeloma.